Has Karen Lorusso, MD received payments from drug or device companies?

Yes. Drug and device makers reported $301,827 in general payments to Karen Lorusso, MD across 287 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Karen Lorusso, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Karen Lorusso, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Karen Lorusso, MD

Hematology & Oncology · Santa Fe, NMNPI 1578562393

Payments from drug & device makers

$301,827in general payments, 2019–2025

Across 287 payments — averaging $1051.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$203K
Merck$94K
Novartis$790
Johnson & Johnson$428
E.r. Squibb & Sons, L.L.C.$331
AbbVie$272
plus $3K from 45 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	31	$202,627
Merck	12	$94,454
Novartis	44	$790
Johnson & Johnson	22	$428
E.r. Squibb & Sons, L.L.C.	20	$331
AbbVie	12	$272
Incyte Corporation	9	$257
Genentech USA, Inc.	12	$228
Seagen Inc.	12	$208
Gilead(2 entities)	10	$199
Karyopharm Therapeutics Inc.	7	$153
Exelixis Inc.	6	$121
Bristol Myers Squibb	6	$116
Pfizer	7	$104
Regeneron Healthcare Solutions, Inc.	3	$102
Puma Biotechnology, Inc.	5	$100
Bayer	5	$88
Mirati Therapeutics, Inc.	3	$85
Servier Pharmaceuticals LLC	4	$83
Takeda Pharmaceuticals U.S.A., Inc.	3	$82
Beigene USA, Inc.	4	$81
Pharmaessentia USA Corporation	4	$79
Sobi, Inc	4	$69
Stemline Therapeutics Inc.	3	$63
Astellas Pharma US Inc	3	$57
Springworks Therapeutics, Inc.	3	$51
AVEO Pharmaceuticals, Inc.	2	$47
GSK	3	$46
Amgen	3	$45
Eisai Inc.	2	$41
Array Biopharma Inc	2	$31
Roche Diagnostics Corporation	2	$30
Daiichi Sankyo Inc.	1	$29
Tempus AI, Inc	1	$27
Pharmacyclics LLC, An Abbvie Company	1	$26
Genmab U.S., Inc.	1	$26
Menarini Silicon Biosystems, Inc.	1	$25
Jazz Pharmaceuticals Inc.	1	$23
Pharming Healthcare, Inc.	1	$22
EMD Serono, Inc.	1	$20
Blueprint Medicines Corporation	1	$19
Taiho Oncology, Inc.	1	$17
Legend Biotech USA Inc.	1	$17
Ipsen Biopharmaceuticals, Inc	1	$15
Myovant Sciences Inc.	1	$15
Caris MPI, Inc.	1	$15
Lilly USA, LLC	1	$14
Fresenius Kabi USA, LLC	1	$14
Morphosys, US Inc.	1	$13
Advanced Accelerator Applications	1	$12
AMAG Pharmaceuticals, Inc.	1	$11

How this compares

$301,827 in reported general payments places this provider in the 75th percentile of 54 hematology & oncology providers in New Mexico.

See all hematology & oncology providers in New Mexico →

Medicare billing

Part B allowed, 2024

$2,398,154

Medicare patients

535

Services billed

62,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Santa Fe

David SnyderSanta Fe$13K
Kathryn ChanSanta Fe$11K
Timothy LopezSanta Fe$3K
Ursa Brown GlabermanAlbuquerque$5M
Neda Hashemi SadraeiAlbuquerque$1.6M
Olivier RixeAlbuquerque$1.6M
Jeffrey NeidhartFarmington$1.5M
Emrullah YilmazAlbuquerque$1.3M
Erika MaestasAlbuquerque$880K
Sardar ImamFarmington$647K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →